Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo.

Chiang KC, Yeh CN, Hsu JT, Yeh TS, Jan YY, Wu CT, Chen HY, Jwo SC, Takano M, Kittaka A, Juang HH, Chen TC.

Cell Cycle. 2013 Apr 15;12(8):1316-25. doi: 10.4161/cc.24445. Epub 2013 Apr 2.

2.

MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.

Chiang KC, Yeh CN, Hsu JT, Chen LW, Kuo SF, Sun CC, Huang CC, Pang JH, Flanagan JN, Takano M, Kittaka A, Juang HH, Yang SW, Chen TC.

J Steroid Biochem Mol Biol. 2013 Nov;138:427-34. doi: 10.1016/j.jsbmb.2013.09.002. Epub 2013 Sep 14.

PMID:
24044969
3.

1α,25(OH)2D3 Analog, MART-10, Inhibits Neuroendocrine Tumor Cell Growth Through Induction of G0/G1 Cell-cycle Arrest and Apoptosis.

Chiang KC, Yeh CN, Pang JH, Hsu JT, Yeh TS, Chen LW, Kuo SF, Hsieh PJ, Pan YC, Takano M, Chen TC, Feng TH, Kittaka A, Juang HH.

Anticancer Res. 2016 Jul;36(7):3307-13.

PMID:
27354587
4.

19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells.

Chiang KC, Yeh CN, Chen HY, Lee JM, Juang HH, Chen MF, Takano M, Kittaka A, Chen TC.

Steroids. 2011 Dec 11;76(13):1513-9. doi: 10.1016/j.steroids.2011.08.006. Epub 2011 Aug 25.

PMID:
21888924
5.

MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.

Chiang KC, Chen SC, Yeh CN, Pang JH, Shen SC, Hsu JT, Liu YY, Chen LW, Kuo SF, Takano M, Kittaka A, Sun CC, Juang HH, Chen TC.

J Steroid Biochem Mol Biol. 2014 Jan;139:54-60. doi: 10.1016/j.jsbmb.2013.10.005. Epub 2013 Oct 12.

PMID:
24125734
6.

Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.

Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC.

Anticancer Res. 2009 Sep;29(9):3547-53. Erratum in: Anticancer Res. 2010 Mar;30(3):1033. Anticancer Res. 2010 Jan;30(1):277.

7.

MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential.

Chiang KC, Kuo SF, Chen CH, Ng S, Lin SF, Yeh CN, Chen LW, Takano M, Chen TC, Juang HH, Kittaka A, Lin JD, Pang JH.

Cancer Lett. 2015 Dec 1;369(1):76-85. doi: 10.1016/j.canlet.2015.07.024. Epub 2015 Aug 14.

PMID:
26282787
8.

MART-10, the new brand of 1α,25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro.

Chiang KC, Sun CC, Chen MH, Huang CY, Hsu JT, Yeh TS, Chen LW, Kuo SF, Juang HH, Takano M, Kittaka A, Chen TC, Yeh CN, Pang JH.

J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):26-34. doi: 10.1016/j.jsbmb.2015.09.022. Epub 2015 Sep 15.

PMID:
26385607
9.

20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.

Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.

Anticancer Res. 1999 May-Jun;19(3A):1689-97.

PMID:
10470102
10.

MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1α,25-Dihydroxyvitamin D(3) in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer Cells.

Chiang KC, Yeh CN, Chen SC, Shen SC, Hsu JT, Yeh TS, Pang JH, Su LJ, Takano M, Kittaka A, Juang HH, Chen TC.

Evid Based Complement Alternat Med. 2012;2012:310872. doi: 10.1155/2012/310872. Epub 2012 Dec 11.

11.

The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells.

Chiang KC, Yeh CN, Hsu JT, Jan YY, Chen LW, Kuo SF, Takano M, Kittaka A, Chen TC, Chen WT, Pang JH, Yeh TS, Juang HH.

Cancer Lett. 2014 Nov 28;354(2):235-44. doi: 10.1016/j.canlet.2014.08.019. Epub 2014 Aug 19.

PMID:
25149065
12.

Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.

Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, White JH.

Mol Endocrinol. 2001 Jul;15(7):1127-39.

PMID:
11435613
13.

Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.

Iglesias-Gato D, Zheng S, Flanagan JN, Jiang L, Kittaka A, Sakaki T, Yamamoto K, Itoh T, Lebrasseur NK, Norstedt G, Chen TC.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):269-75. doi: 10.1016/j.jsbmb.2011.08.010. Epub 2011 Sep 3.

PMID:
21911059
14.

MART-10, a newly synthesized vitamin D analog, represses metastatic potential of head and neck squamous carcinoma cells.

Yang SW, Tsai CY, Pan YC, Yeh CN, Pang JH, Takano M, Kittaka A, Juang HH, Chen TC, Chiang KC.

Drug Des Devel Ther. 2016 Jun 17;10:1995-2002. doi: 10.2147/DDDT.S107256. eCollection 2016.

15.

19-Norvitamin D analogs for breast cancer therapy.

Matsumoto Y, Kittaka A, Chen TC.

Can J Physiol Pharmacol. 2015 May;93(5):333-48. doi: 10.1139/cjpp-2014-0452. Epub 2015 Mar 6. Review.

PMID:
25918960
16.

Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.

Yoon JS, Kim JY, Park HK, Kim ES, Ahn KS, Yoon SS, Cho CG, Kim BK, Lee YY.

Int J Oncol. 2008 Feb;32(2):387-96.

PMID:
18202761
17.

24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.

Shiohara M, Uskokovic M, Hisatake J, Hisatake Y, Koike K, Komiyama A, Koeffler HP.

Cancer Res. 2001 Apr 15;61(8):3361-8.

18.

Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo.

Verlinden L, Verstuyf A, Van Camp M, Marcelis S, Sabbe K, Zhao XY, De Clercq P, Vandewalle M, Bouillon R.

Cancer Res. 2000 May 15;60(10):2673-9.

19.
20.

5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.

Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP.

Cancer Res. 1999 Aug 15;59(16):4023-9.

Supplemental Content

Support Center